Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform
Both bring longstanding track records of successfully leading trailblazing biotechnology companies with an emphasis on gene editing and novel technologies.
- Both bring longstanding track records of successfully leading trailblazing biotechnology companies with an emphasis on gene editing and novel technologies.
- In addition, their combined experience will be instrumental in establishing Seamless Therapeutics’ Research and Development (R&D) activities in the US.
- Early in vivo preclinical evidence has shown that Seamless’ programmable recombinases can precisely edit a 138 kilobase fragment through inversion.
- “Seamless Therapeutics is at the forefront of the next wave of innovation in gene editing with its unique platform and comprehensive toolbox capable of programming recombinases.